Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy.
about
Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical TrialsImproving clinical trial design for Duchenne muscular dystrophy.Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.Circulating Biomarkers for Duchenne Muscular Dystrophy.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Translational development of splice-modifying antisense oligomers.Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test.Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy.Detection of early nocturnal hypoventilation in neuromuscular disorders.226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy.
P2860
Q31142754-C76E12E1-FCAC-43BE-8EA7-84FB115B59CFQ35755174-2EB0D7E6-08C5-4441-8CD8-B73B5F4DE9C6Q36603337-1D4C69DD-AC32-4A33-87F0-F036D0493745Q37114363-AA147DD5-8CA4-4B98-A1FA-BF6949ECAE0FQ37610530-30147F1A-9989-4667-92A5-33F0948BBB5CQ38302852-0B5CD99D-592E-4A78-9F51-4B602B1ED020Q38996657-28430E43-CA38-4D60-88FD-D0D804012ABAQ40219200-93CF3040-7B15-4D16-A580-724D15D35BBAQ41145500-0C9EE0EF-A80B-4170-8AAD-DA4464EE8EC2Q47177918-4322AB63-3051-4CCF-9B1C-1BE8BA116347Q47656688-D6B1B553-C4C4-4C09-8962-E0178ACFBE72Q48543939-F626F98D-4863-470D-8F19-3BE1E76CF6C3Q55282480-631EB8C3-2B67-4BD8-9C58-170B2F1DC058
P2860
Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@en
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@nl
type
label
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@en
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@nl
prefLabel
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@en
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@nl
P2093
P50
P1476
Measuring clinical effectivene ...... f Duchenne muscular dystrophy.
@en
P2093
Anna Mayhew
Elizabeth Vroom
Eugenio Mercuri
Jan Verschuuren
Kate Bushby
Marita Pohlschmidt
Nathalie Goemans
Pat Furlong
Stephen Lynn
Thomas Voit
P304
P356
10.1016/J.NMD.2014.09.003
P50
P577
2014-09-11T00:00:00Z